Vaxcyte, Inc. Common Stock (NASDAQ:PCVX) · earnings preview
Quarter
Q3
EPS estimate to actual
-$2.06
At a glance
Key takeaways
01Vaxcyte (PCVX) will report Q3 2026 earnings on November 3 after market close, with analysts expecting a loss of $2.06 per share.
02The stock trades at $60.65 with a $5.8 billion market capitalization despite consistent quarterly losses over the past year.
03Recent earnings history shows PCVX has missed estimates in three of the last four quarters, with Q1 missing by 28.5% and Q4 by 20.8%.
04Investors should focus on revenue trends, margin performance, and forward guidance rather than the headline EPS number alone.
Earnings Results
Vaxcyte, Inc. Common Stock (NASDAQ:PCVX) is scheduled to report its Q3 earnings results on November 03, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-2.06, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $60.65 with a market capitalization of $5.8B.
Ahead of Vaxcyte, Inc. Common Stock's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Vaxcyte, Inc. Common Stock should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.